(Q43666866)

25 November 2017

title

A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation (English)

1 reference

25 November 2017

main subject

liver transplantation

1 reference

1 reference

R J Fontana

1

1 reference

25 November 2017

H W Hann

2

1 reference

25 November 2017

T Wright

3

1 reference

25 November 2017

G Everson

4

1 reference

25 November 2017

A Baker

5

1 reference

25 November 2017

E R Schiff

6

1 reference

25 November 2017

C Riely

7

1 reference

25 November 2017

G Anschuetz

8

1 reference

25 November 2017

M Riker-Hopkins

9

1 reference

25 November 2017

N Brown

10

1 reference

25 November 2017

Lamivudine Compassionate Use Study Group

11

1 reference

25 November 2017

publication date

1 June 2001

1 reference

25 November 2017

published in

Liver Transplantation

1 reference

25 November 2017

volume

7

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

504-510

1 reference

Hepatitis B: Evolving Epidemiology and Implications for Control

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

Treatment of fibrosing cholestatic hepatitis with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24896

21 January 2018

Identifiers

DOI

10.1053/JLTS.2001.24896

1 reference

25 November 2017

1 reference